<DOC>
	<DOCNO>NCT00005849</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness bryostatin 1 plus paclitaxel treating patient stage IIIB , stage IV , recurrent non-small cell lung cancer .</brief_summary>
	<brief_title>Bryostatin 1 Plus Paclitaxel Treating Patients With Stage IIIB , Stage IV , Recurrent Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine overall , partial , complete response rate patient stage IIIB-IV recurrent non-small cell lung cancer treat bryostatin 1 paclitaxel . II . Determine overall survival time tumor progression patient treat regimen . III . Determine T cell subset analysis serum level interleukin-6 tumor necrosis factor alpha patient receive bryostatin 1 correlate clinical endpoint . OUTLINE : This multicenter study . Patients receive paclitaxel IV 1 hour day 1 , 8 , 15 bryostatin 1 IV 1 hour day 2 , 9 , 16 . Treatment repeat every 4 week minimum 2 course absence disease progression unacceptable toxicity . Patients follow least 2 year survival . PROJECTED ACCRUAL : A total 15-40 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Bryostatin 1</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven stage IIIB , IV recurrent nonsmall cell lung cancer ( NSCLC ) Patients stage IIIB disease must pleural effusion Measurable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Karnofsky 50100 % Life expectancy : Not specify Hematopoietic : WBC great 3,000/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin normal SGOT le 2 time normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 50 mL/min Blood urea nitrogen le 1.5 time normal Cardiovascular : No symptomatic congestive heart failure , unstable angina pectoris , myocardial infarction within past 6 month No heart block bad first degree , bundle branch block , ventricular supraventricular arrhythmia 12 lead electrocardiogram Other : Not pregnant nursing Fertile patient must use effective contraception No uncontrolled concurrent illness include , limited , ongoing active infection PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent colonystimulating factor Chemotherapy : No prior chemotherapy NSCLC Endocrine therapy : Not specify Radiotherapy : Greater 4 week since prior radiotherapy Surgery : Not specify Other : No concurrent investigational agent No concurrent antiretroviral therapy ( HAART ) HIV positive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>